Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study.

Sorry, there's nothing here.

Cite this paper

@article{Michon1994AdministrationOH, title={Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study.}, author={Jean M. Michon and Sylvie N{\'e}grier and Carole Coze and Claire Mathiot and Didier Frappaz and Ralph Oskam and H{\'e}l{\`e}ne D Pacquement and Erica Quintana and Eric Bouffet and J. L. Bernard}, journal={Progress in clinical and biological research}, year={1994}, volume={385}, pages={293-300} }